alpha-aminopyridine has been researched along with Depression, Involutional in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Burdick, KE; Fava, M; Johe, KK; Kay, G; Kumar, S; McIntyre, RS; Papakostas, GI | 1 |
| Johe, K; Lee, Y; McIntyre, RS; Rong, C | 1 |
| Alsiö, J; Bussey, TJ; Dewan, S; Heath, CJ; Nilsson, SRO; Phillips, BU; Robbins, TW; Saksida, LM | 1 |
| Drouillard, A; Fava, M; Flynn, M; Hand, H; Hoeppner, B; Johe, K; Kashambwa, R; Kay, G; Martinson, MA; Papakostas, GI; Russo, P; Yeung, A | 1 |
| Bilello, JA; Dickerson, BC; English, BA; Ereshefsky, L; Fava, M; Flynn, M; Freeman, MP; Gertsik, LG; Hoeppner, BB; Johe, K; Johnstone, J; Kinrys, G; Makris, N; Mischoulon, D; Thurmond, LM | 1 |
| Bagby, RM; Carella, A; Dunn, E; Houle, S; Hussey, D; Lee, M; Meyer, JH; Praschak-Rieder, N; Willeit, M; Wilson, AA | 1 |
1 review(s) available for alpha-aminopyridine and Depression, Involutional
| Article | Year |
|---|---|
The neurogenic compound, NSI-189 phosphate: a novel multi-domain treatment capable of pro-cognitive and antidepressant effects.
Topics: Adult; Aminopyridines; Animals; Antidepressive Agents; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Hippocampus; Humans; Neurogenesis; Piperazines | 2017 |
4 trial(s) available for alpha-aminopyridine and Depression, Involutional
| Article | Year |
|---|---|
NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder.
Topics: Adult; Aminopyridines; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Neurogenesis; Piperazines; Severity of Illness Index | 2020 |
A phase 2, double-blind, placebo-controlled study of NSI-189 phosphate, a neurogenic compound, among outpatients with major depressive disorder.
Topics: Aminopyridines; Cognition; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Outpatients; Piperazines; Treatment Outcome | 2020 |
A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.
Topics: Adult; Aminopyridines; Biomarkers, Pharmacological; Depression; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2016 |
Tryptophan depletion and serotonin loss in selective serotonin reuptake inhibitor-treated depression: an [(18)F] MPPF positron emission tomography study.
Topics: Adult; Aminopyridines; Brain; Brain Mapping; Depressive Disorder, Major; Double-Blind Method; Fluorine Radioisotopes; Humans; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Radiochemistry; Selective Serotonin Reuptake Inhibitors; Serotonin; Tryptophan | 2004 |
1 other study(ies) available for alpha-aminopyridine and Depression, Involutional
| Article | Year |
|---|---|
Selective effects of 5-HT2C receptor modulation on performance of a novel valence-probe visual discrimination task and probabilistic reversal learning in mice.
Topics: Aminopyridines; Animals; Azepines; Depressive Disorder, Major; Discrimination Learning; Indoles; Male; Mice; Probability Learning; Receptor, Serotonin, 5-HT2C; Reinforcement, Psychology; Reversal Learning; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Task Performance and Analysis; Visual Perception | 2018 |